Description
ZYKADIA 150MG CAPSULES
First action · last action
2014-06-24 · 2015-07-18
Transactions
3
First transaction's obligation
$57,015
Base + all options value (sum of deltas)
$28,507
Extent competed
NOT COMPETED
Other than full & open authority
URGENCY
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
325414 · BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2014-06-24+$57,015= $57,015
- Mod P000012014-07-30-$14,254= $42,761
- Mod P000022015-07-18-$14,254= $28,507
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2014-06-24 | +$57,015 | $57,015 | ZYKADIA 150MG CAPSULES |
| Mod P00001· OTHER ADMINISTRATIVE ACTION | 2014-07-30 | −$14,254 | $42,761 | ZYKADIA 150MG CAPSULES |
| Mod P00002· OTHER ADMINISTRATIVE ACTION | 2015-07-18 | −$14,254 | $28,507 | ZYKADIA 150MG CAPSULES |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI GVRYEDLFU6J3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C26126P0068 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $29,628 | FY2026 |
| 36C26125P1616 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $18,697 | FY2025 |
| 36C26125P1544 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $77,456 | FY2025 |
| 36C25925P1069 | NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS | $10,035 | FY2025 |
| 36C26223P0842 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36C24222P0293 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $10,296 | FY2022 |
Other recipients under 6505 from 583-INDIANAPOLIS (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA25116F0847 | ACTELION PHARMACEUTICALS US, INC. | 583-INDIANAPOLIS | $4,614 | FY2016 |
| VA25116F0730 | CSL BEHRING L.L.C. | 583-INDIANAPOLIS | $26,724 | FY2016 |
| VA25116F0509 | CSL BEHRING L.L.C. | 583-INDIANAPOLIS | $26,724 | FY2016 |
| VA25116F0406 | ROCHE DIAGNOSTICS CORPORATION | 583-INDIANAPOLIS | $17,601 | FY2016 |
| VA25116P0414 | ASD SPECIALTY HEALTHCARE, LLC | 583-INDIANAPOLIS | $35,317 | FY2016 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA25114P2168_3600_-NONE-_-NONE- · retrieved 2026-09-27.